193 related articles for article (PubMed ID: 35186258)
1. Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes.
Pungor K; Bozikas VP; Emsley R; Llorca PM; Gopal S; Mathews M; Wooller A; Bergmans P
Ther Adv Psychopharmacol; 2020; 10():2045125320981500. PubMed ID: 35186258
[TBL] [Abstract][Full Text] [Related]
2. Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia.
Garcia-Portilla MP; Llorca PM; Maina G; Bozikas VP; Devrimci-Ozguven H; Kim SW; Bergmans P; Usankova I; Pungor K
Ther Adv Psychopharmacol; 2020; 10():2045125320926347. PubMed ID: 32518617
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study.
Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Hough D; Mathews M; Feng Y; Yu L; Takahashi M; Liu D; Wang G; Yoon JS; Chen JJ
Neuropsychiatr Dis Treat; 2017; 13():2193-2207. PubMed ID: 28860777
[TBL] [Abstract][Full Text] [Related]
4. Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.
Mathews M; Pei H; Savitz A; Nuamah I; Hough D; Alphs L; Gopal S
Clin Drug Investig; 2018 Aug; 38(8):695-702. PubMed ID: 29882073
[TBL] [Abstract][Full Text] [Related]
5. Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate.
Lencer R; Garcia-Portilla MP; Bergmans P; Gopal S; Mathews M; Wooller A; Pungor K
Compr Psychiatry; 2021 May; 107():152233. PubMed ID: 33711781
[TBL] [Abstract][Full Text] [Related]
6. Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia.
Lambert M; Sanchez P; Bergmans P; Gopal S; Mathews M; Wooller A; Pungor K
Neuropsychiatr Dis Treat; 2020; 16():3197-3208. PubMed ID: 33380797
[TBL] [Abstract][Full Text] [Related]
7. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia.
Gopal S; Vermeulen A; Nandy P; Ravenstijn P; Nuamah I; Buron Vidal JA; Berwaerts J; Savitz A; Hough D; Samtani MN
Curr Med Res Opin; 2015 Nov; 31(11):2043-54. PubMed ID: 26306819
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.
Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Janik A; Schotte A; Hough D; Fleischhacker WW
Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 26902950
[TBL] [Abstract][Full Text] [Related]
9. Asian Subgroup Analysis of the REMISSIO Study: A Long-Term Efficacy and Safety Study of Paliperidone Palmitate 3-month Formulation in Patients with Stable Schizophrenia in a Naturalistic Clinical Setting.
Chung YC; Yang YK; Sulaiman AH; Bergmans P; Tan W
Clin Psychopharmacol Neurosci; 2022 Aug; 20(3):427-439. PubMed ID: 35879027
[TBL] [Abstract][Full Text] [Related]
10. Discontinuation and relapse with paliperidone palmitate three-monthly for maintenance of schizophrenia: Two year follow-up of use in clinical practice.
Wallman P; Clark I; Taylor D
J Psychopharmacol; 2021 Sep; 35(9):1091-1098. PubMed ID: 33908302
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of paliperidone palmitate long-acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia.
Brown B; Turkoz I; Mancevski B; Mathews M
Early Interv Psychiatry; 2020 Aug; 14(4):428-438. PubMed ID: 31515972
[TBL] [Abstract][Full Text] [Related]
12. Effect of 3-monthly paliperidone palmitate on hospitalisation in a naturalistic schizophrenia cohort - A five-year mirror image study.
Wallman P; Clark I; Taylor D
J Psychiatr Res; 2022 Apr; 148():131-136. PubMed ID: 35123325
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study.
Giron-Hernandez C; Han JH; Alberio R; Singh A; García-Portilla MP; Pompili M; Knight RK; Richarz U; Gopal S; Antunes J
Neuropsychiatr Dis Treat; 2023; 19():895-906. PubMed ID: 37077705
[TBL] [Abstract][Full Text] [Related]
14. A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia.
Najarian D; Sanga P; Wang S; Lim P; Singh A; Robertson MJ; Cohen K; Schotte A; Milz R; Venkatasubramanian R; T'Jollyn H; Walling DP; Galderisi S; Gopal S
Int J Neuropsychopharmacol; 2022 Mar; 25(3):238-251. PubMed ID: 34791283
[TBL] [Abstract][Full Text] [Related]
15. Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation.
Nash AI; Turkoz I; Savitz AJ; Mathews M; Kim E
Neuropsychiatr Dis Treat; 2019; 15():731-737. PubMed ID: 30962688
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies.
Mathews M; Gopal S; Singh A; Nuamah I; Pungor K; Tan W; Soares B; Kim E; Savitz AJ
Neuropsychiatr Dis Treat; 2020; 16():1533-1542. PubMed ID: 32606705
[TBL] [Abstract][Full Text] [Related]
17. Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate.
Lin D; Pilon D; Zhdanava M; Joshi K; Lafeuille MH; Côté-Sergent A; Vermette-Laforme M; Lefebvre P
Curr Med Res Opin; 2021 Apr; 37(4):675-683. PubMed ID: 33507838
[TBL] [Abstract][Full Text] [Related]
18. Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority study.
Savitz AJ; Xu H; Gopal S; Nuamah I; Hough D; Mathews M
Int Clin Psychopharmacol; 2017 Nov; 32(6):329-336. PubMed ID: 28806194
[TBL] [Abstract][Full Text] [Related]
19. Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis.
Patel C; El Khoury A; Huang A; Wang L; Baser O; Joshi K
Adv Ther; 2019 Oct; 36(10):2941-2953. PubMed ID: 31396809
[TBL] [Abstract][Full Text] [Related]
20. Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate.
Mathews M; Nuamah I; Savitz AJ; Hough DW; Najarian D; Kim E; Gopal S
Neuropsychiatr Dis Treat; 2018; 14():2807-2816. PubMed ID: 30498351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
